Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06470633 | To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer | not yet recruiting | Phase 2 | 29 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jun 24, 2024 | clinicaltrials |
| NCT05720260 | Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC | recruiting | Phase 2 | 42 | National Taiwan University HospitalOTHER | 1 | Jun 10, 2024 |
| clinicaltrials |
| NCT03815890 | Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO(BELLINI) | recruiting | Phase 2 | 80 | The Netherlands Cancer InstituteOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06389006 | To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer | recruiting | Phase 2 | 79 | RemeGen Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT06407310 | Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 25 | Tel Aviv Medical CenterOTHER | 0 | May 9, 2024 | clinicaltrials |
| NCT06404697 | Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients | recruiting | Phase 2 | 24 | Ruijin HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06404736 | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer(QUEEN-Dream) | not yet recruiting | Phase 2 | 73 | Fudan UniversityOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05033756 | Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO(COMPRENDO) | active not recruiting | Phase 2 | 11 | Institut fuer FrauengesundheitOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT03982485 | Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer(APP) | active not recruiting | Phase 2 | 196 | RenJi HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06385990 | Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy | recruiting | Phase 2 | 53 | Hunan Cancer HospitalOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06339281 | A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer | not yet recruiting | Phase 2 | 68 | Li HuipingOTHER | 0 | Apr 19, 2024 | clinicaltrials |
| NCT06371807 | Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab(KEYPARTNER) | not yet recruiting | Phase 2 | 20 | Fundacao ChampalimaudOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06149130 | Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer | recruiting | Phase 2 | 82 | Tongji HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06354114 | A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011 | not yet recruiting | Phase 2 | 80 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06341894 | Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer | recruiting | Phase 2 | 1,163 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05986071 | I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers(MATRIX) | not yet recruiting | Phase 1 / Phase 2 | 57 | Institut Paoli-CalmettesOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT05861271 | Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer | recruiting | Phase 2 | 1,008 | Fudan UniversityOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06227117 | Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer | recruiting | Phase 2 | 120 | RemeGen Co., Ltd.INDUSTRY | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06202261 | A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 154 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06268327 | Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy | not yet recruiting | Phase 2 / Phase 3 | 30 | Assiut UniversityOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT06254690 | The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study | recruiting | Phase 2 | 102 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05949541 | Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer(BCTOP-L-M01) | recruiting | Phase 2 | 265 | Fudan UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06229067 | Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 182 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 29, 2024 | clinicaltrials |
| NCT06169072 | Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients(MagSnow2) | recruiting | Phase 2 | 220 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT02641847 | TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature | active not recruiting | Phase 2 / Phase 3 | 503 | Fudan UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT02965950 | The p53 Breast Cancer Trial(p53b) | active not recruiting | Phase 2 | 190 | Haukeland University HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT06202313 | Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 128 | Shengjing HospitalOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT06165900 | Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC | recruiting | Phase 2 | 136 | Shengjing HospitalOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06001086 | A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer | recruiting | Phase 2 | 70 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05978648 | Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy(SMA-BC-002) | recruiting | Phase 2 | 116 | wang shusenOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT05451784 | Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS(TILS001) | recruiting | Phase 1 / Phase 2 | 20 | Fundacio Clinic BarcelonaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT06140576 | The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial. | not yet recruiting | Phase 1 / Phase 2 | 58 | Zhejiang Cancer HospitalOTHER | 1 | Nov 20, 2023 | clinicaltrials |
| NCT04172259 | ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC | active not recruiting | Phase 2 | 156 | Sun Yat-sen UniversityOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT05569811 | NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial(VALENTINE) | active not recruiting | Phase 2 | 120 | SOLTI Breast Cancer Research GroupOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06023277 | A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 40 | Jacinto Convit World Organization Inc.OTHER | 2 | Sep 5, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT06000917 | A Study of Neoadjuvant TCHpy(Pyrotinib ,Trastuzumab,Carboplatin and Paclitaxel)for ER+/HER2+ Breast Cancer | recruiting | Phase 2 | 62 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05983094 | Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer | not yet recruiting | Phase 2 | 181 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05981001 | Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 170 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05981014 | Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 196 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05979220 | Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy | not yet recruiting | Phase 2 | 178 | Shuangyue LiuOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT00909909 | Radiation Therapy in Treating Women With Early Stage Breast Cancer | active not recruiting | Phase 2 | 200 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05862610 | The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC | not yet recruiting | Phase 2 | 150 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 24, 2023 | clinicaltrials |
| NCT05824325 | Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer(GALAXY) | active not recruiting | Phase 1 / Phase 2 | 56 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05447702 | Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | recruiting | Phase 2 | 35 | West China HospitalOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05834764 | Pyrotinib in Women With High-risk in Early Stage Breast Cancer | recruiting | Phase 2 | 188 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05804916 | Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer | recruiting | Phase 2 / Phase 3 | 556 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT02315196 | Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | active not recruiting | Phase 2 | 62 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 29, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 24, 2024source: clinicaltrials